与传统异基因干细胞移植相比,减低强度预处理用于复发或难治性霍奇金淋巴瘤的疗效分析:欧洲血液与骨髓移植组淋巴瘤工作组的一项研究
Reduced-intensity conditioning compared with conventional allogeneic stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma: an analysis from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation.
作者信息
Sureda Anna, Robinson Stephen, Canals Carmen, Carella Angelo M, Boogaerts Marc A, Caballero Dolores, Hunter Ann E, Kanz Lothar, Slavin Shimon, Cornelissen Jan J, Gramatzki Martin, Niederwieser Dietger, Russell Nigel H, Schmitz Norbert
机构信息
Clinical Hematology Division, Hospital de la Santa Creu i Sant Pau, Antoni Maria i Claret, 167, 08025 Barcelona, Spain.
出版信息
J Clin Oncol. 2008 Jan 20;26(3):455-62. doi: 10.1200/JCO.2007.13.2415. Epub 2007 Dec 17.
PURPOSE
To compare the clinical outcome in terms of nonrelapse mortality (NRM), relapse rate (RR), overall survival (OS), and progression-free survival (PFS) in patients with relapsed Hodgkin's lymphoma (HL) treated with reduced-intensity conditioning (RIC) or myeloablative conditioning followed by allogeneic stem-cell transplantation (alloSCT).
PATIENTS AND METHODS
A total of 168 patients with HL undergoing a first alloSCT (RIC, n = 89; myeloablative conditioning, n = 79) between January 1997 and December 2001 and registered in the European Group for Blood and Marrow Transplantation database were analyzed.
RESULTS
NRM was significantly decreased in the RIC group (hazard ratio [HR], 2.85; 95% CI, 1.62 to 5.02; P < .001). OS was better in the RIC group (HR, 2.05; 95% CI, 1.27 to 3.29; P = .04) and there was a trend for better PFS in the RIC group (HR, 1.53; 95% CI, 0.97 to 2.40; P = .07). RR was higher in the RIC group in univariate but not in multivariate analysis. The development of chronic graft-versus-host disease (GVHD) significantly decreased the incidence of relapse, which translated into a trend for a better PFS.
CONCLUSION
The lower incidence of NRM in the RIC group is encouraging, particularly because these patients experienced adverse pretransplantation characteristics more frequently. This analysis also indicates the existence of a graft-versus-HL effect correlated to the development of GVHD. Additional efforts to reduce the high RR seen in both groups of patients will be necessary to improve the modest PFS (31% v 27%) and OS (59% v 36%) for patients prepared with RIC or myeloablative conditioning.
目的
比较接受减低强度预处理(RIC)或清髓性预处理后行异基因干细胞移植(alloSCT)的复发霍奇金淋巴瘤(HL)患者的非复发死亡率(NRM)、复发率(RR)、总生存期(OS)和无进展生存期(PFS)方面的临床结局。
患者和方法
分析了1997年1月至2001年12月期间在欧洲血液和骨髓移植组数据库登记的168例首次接受alloSCT的HL患者(RIC组,n = 89;清髓性预处理组,n = 79)。
结果
RIC组的NRM显著降低(风险比[HR],2.85;95%可信区间[CI],1.62至5.02;P <.001)。RIC组的OS更好(HR,2.05;95%CI,1.27至3.29;P =.04),RIC组的PFS有更好的趋势(HR,1.53;95%CI,0.97至2.40;P =.07)。单因素分析中RIC组的RR较高,但多因素分析中并非如此。慢性移植物抗宿主病(GVHD)的发生显著降低了复发率,这转化为PFS有更好的趋势。
结论
RIC组较低的NRM发生率令人鼓舞,特别是因为这些患者更频繁地出现移植前不良特征。该分析还表明存在与GVHD发生相关的移植物抗HL效应。为改善接受RIC或清髓性预处理患者适度的PFS(31%对27%)和OS(59%对36%),有必要进一步努力降低两组患者中都较高的RR。